Portal hypertension: State of the art

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 4, 1999, Pages 326-345

  Gatta, A ^a   Sacerdoti, D ^a   Bolognesi, M ^a   Merkel, C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

blockers; Hyperdynamic syndrome; Intrahepatic resistance; Portal hypertension; Portal pressure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; ENDOTHELIN; NITRIC OXIDE; PROSTAGLANDIN; SOMATOSTATIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN;

COLLATERAL CIRCULATION; COLOR ULTRASOUND FLOWMETRY; ESOPHAGUS VARICES; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; SPLANCHNIC BLOOD FLOW; VEIN RESISTANCE;

HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; PORTAL PRESSURE; SPLANCHNIC CIRCULATION;

EID: 0033042142     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (199)

1. Bradley SE, Ingelfinger FJ, Bradley GP. Hepatic circulation in cirrhosis of the liver. Circulation 1952;5:419-29.
2. Moreno AH, Burchell AR, Rousselot LM, Panke WF, Slafsky F, Bulke JH. Portal blood flow in cirrhosis of the liver. J Clin Invest 1967;46:436-45.
3. Bhathal PS, Groszmann HJ. Reduction of the increased portal vascular resistance of isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985:1:325-37.
4. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997:25:2-5.
5. Jimenez \V, Rodes H. Impaired responsiveness to endogenous vasoconstrictors and endothelium derived vasoactive factors in cirrhosis. Gastroenterology 1994;107:1201-3.
6. Pinzani M, Milani S, De Franco R, Grappone C, Caligiuri A, Gentilini A, et al. Endothelin 1 overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996;110:534-8.
7. Zhang B, Calmus Y, Wen L, Sogni P, Lotersztajn S, Houssin D, et al. Endothelin-1 induces liver vasoconstriction through both ETA and ETB receptors. J Hepatol 1997;26:1104-10.
8. Rockey DC, Chung JJ. Reduced nitric oxide production by en-dothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-51.
9. Suematsu M, Kashiwagi S, Sano T, Goda N, Shinoda Y, Ishimura Y. Carbon monoxide as an endogenous modulator of hepatic vascular perfusion. Biochem Biophys Res Comm 1994;205:1333-7.
10. Suematsu M, Goda N, Sano T, Kashiwagi S, Egawa T, Shinoda Y, et al. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 1995;96:2431-7.
11. Marteau P, Ballet F, Chazovilleres O. Effect of vasodilators on hepatic circulation in cirrhosis: a study in the isolated perfused rat liver. Hepatology 1989;8:820-3.
12. Poo JL, Braillon A, Hadengue A, Gaudin C, Lebrec D. Hemodynamic effects of terbutaline, a β2-adrenoreceptor agonist, in conscious rats with secondary biliary cirrhosis. Hepatology 1992;15:459-63.
13. Cummings SA, Groszmann RJ, Kaumann AJ. Hypersensitivity of mesenteric veins to 5-hydroxytryptamine and ketanserin-induced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol 1986;89:501-13.
14. Garcia-Pagan JC, Feu F, Navasa M, Bru C, Ruiz de Arbol L, Bosch J, et al. Long-term haemodynamic effect of isosorbide-5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990;11:189-95.
15. Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the β-blocker alone. Hepatology 1997;26:34-9.
16. Sacerdoti D, Merkel C, Bolognesi M, Amodio P, Angeli P, Gatta A. Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: relationship with portal hemodynamics. Gastroenterology 1995;108:1152-8.
17. Bolognesi M, Sacerdoti D, Merkel C, Gatta A. Relationship between portal blood flow measured by image-directed Doppler ultrasonography and hepatic blood flow measured by indocyanine green constant infusion in patients with cirrhosis. J Clin Ultrasound 1995;23:297-303.
18. Tisdale WA, Klatskin G, Glenn WW. Portal hypertension and bleeding esophageal varices: their occurrence in the absence of both intrahepatic and extrahepatic obstruction of the portal vein. N Eng J Med 1959:261:209-18.
19. Gitlin N, Grahame GR, Kreel L, Williams HS, Sherlock S. Splenic blood flow and resistance in patients with cirrhosis before and after portacaval anastomoses. Gastroenterology 1970:59:208-13.
20. Witte CL, Witte MH, Bair G, Mobley WP, Morton D. Experimental study of hyperdynamic vs. stagnant mesenteric blood flow in portal hypertension. Ann Surg 1974;179:304-10.
21. Vorobioff J, Bredfeld J, Groszmann RJ. Hyperdynamic circulation in a portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;224:G52-60.
22. rd Congresso Società Italiana Medicina Interna - Vol. II. Rome: Ed. Pozzi; 1992. p. 303-26.
23. Bemardi M, Trevisani F. Systemic and regional hemodynamics in pre-ascitic cirrhosis. J Hepatol 1997;27:588-91.
24. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal venous hypertension. Semin Liver Dis 1986;6:287-91.
25. Sherwin R, Joshi P, Hendler R, Feiig P, Conn HO. Hyperglucagonemia in Lannec's cirrhosis. The role of portal-systemic shunt. N Engl J Med 1974;290:239-42.
26. Benoit JN, Womack WA, Heraandez L, Granger DN. "Forward" " and "backward" flow mechanisms of portal hypertension. Rela-live contributions in a rat model of portal vein stenosis. Gastroenterology 1985;89:1092-6.
27. Gibson PR, Dudley FJ. Pathophysiology of portal hypertension and implications for its pharmacological control. Aust NZ J Med 1989;19:172-82.
28. n Macdougall BRD, Westaby D, Blendis LA. Portal hypertension: 25 years of progress. Gut 1991;(Suppl.):18-24.
29. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis. A role for nitric oxide. Lancet 1991;i:776-8.
30. Bosch J, Pizcueta P, Feu F, Fernandez H, Garcia-Pagan CG. Pathophysiology of portal hypertension. Gastroenterol Clin N Amer 1992;21:1-14.
31. Sogni P, Moreau R, Gadano A, Lebrec D. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol 1995;23:218-24.
32. Hori N, Okanoue T, Sawa Y, Kashima K. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J Hepatol 1997;26:1111-9.
33. Garcia-Pagan JC, Bosch J, Rodes J. The role of vasoactive mediators in portal hypertension. Semin Liver Dis 1995;6:140-7.
34. Pak JM, Lee SS. Glucagon in portal hypertension. J Hepatol 1994;20:825-32.
35. Kravetz D, Bosch J, Arderiu MT, Pizcueta MP, Casamitjana R, Rivera F, et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988;254:G322-8.
36. Malesci A, Tacconi M, Valentini A, Basilico M, Lorenzano E, Salerno F. Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function. J Hepatol 1987;26:816-25.
37. Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997;26:75-80.
38. Bruix J, Bosch J, Kravetz D, Mastai R, Rodes J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985:88:430-5.
39. Bosch J, Arroyo V, Betriu A, Mas A, Rivera F, Navaro-Lopez J, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980;78:92-9.
40. Zimmon DS, Kessler RE. The portal pressure-blood volume relationship in cirrhosis. Gut 1974:15:99-101.
41. Angeli P, Caregaro L, Menon F, Sacerdoti D, De Toni R, Merkel C, et al. Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: pathophysiological and clinical implications. Hepatology 1992;16:1389-94.
42. Lieberman FL, Reynolds T. Plasma volume in cirrhosis of the liver: its relation to portal hypertension, ascites and renal failure. J Clin Invest 1967;46:1297-308.
43. Weisberg H, Rosenthal WS, Glass GBJ. The effect of diuretic therapy on portal pressure in cirrhotic patients with and without ascites. Am J Dig Dis 1965:10:239-99.
44. Rector WG, Ibarra F. Intravascular volume in cirrhosis. Reassessment using improved methodology. Dig Dis Sci 1988;33:460-6.
45. Boyer JL, Chatterjee C, Iber FL, Basu AK. Effect of plasma-volume expansion on portal hypertension. N Engl J Med 1966:275:750-5.
46. Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during haemorrhage and blood volume restitution. Gastroenterology 1986;90:1232-40.
47. Bemuau T. Traitement de l'hypovolémie après une hémorragie digestive haute par hypertension portal au cours de la cirrhose. Gastroenterol Clin Biol 1990;14:25-8.
48. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henrikson JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposai for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
49. Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, et al. Reduction in hepatic vein pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52.
50. Garcia-Pagan JC, Salmeron JM, Feu F, Gines A, Cirera I, Jimenez W, et al. Spironolactone decreases portal pressure in patients with compensated cirrhosis. J Hepatol 1991;13(Suppl.2):S30.
51. Blendis LM. Portal hypertension. In: Lautt WW, editor. Hepatic circulation in health and disease. New York: Raven Press; 1981. p. 329-50.
52. Armonis A, Patch D, Burroughs A. Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? Hepatology 1997;25:245-8.
53. Moriyasu F, Nishida O, Ban N, NakamuraT, Sakai M, Miyake T, et al. "Congestion index" of the portal vein. Am J Roentgenol 1986;146:735-9.
54. Rigau J, Bosch J, Bordas JM, Navasa M, Mastai R, Kravetz D, et al. Endoscopie measurement of variceal pressure in cirrhosis: correlation with portal pressure and variceal hemorrhage. Gastroenterology 1989;96:873-82.
55. Nevens F, Bustami R, Scheys I, Lesaffre E, Fevery J. Variceal pressure is a factor predicting the risk of a first variceal bleeding: a prospective cohort study in cirrhotic patients. Hepatology 1998;27:15-9.
56. Kleber G, Sauerbruch T, Ansari H, Paumgartner G. Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study. Gastroenterology 1991;100(5 Pt l):1332-7.
57. North Italian Endoscopie Club for the Study and Treatment of Esophageal Varices. Prediction of first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988;319:983-9.
58. Bolondi L, Gandolfi L, Arienti V, Caletti GC, Corcioni E, Gasbarrini G, et al. Ultrasonography in the diagnosis of portal hypertension: diminished response of portal vessels to respiration. Radiology 1982;142:167-72.
59. Weinreb J, Kumari S, Phillips G, Pochaczvesky R. Portal vein measurement by real-time sonography. Am J Roentgenol 1982;139:497-9.
60. Lafortune M, Marleau D, Breton G, Viallet A, Lavoie P, Huet PM. Portal venous measurements in portal hypertension. Radiology 1984; 151:27-30.
61. Cottone M, Sciarrino E, Marceno MP, Maringhini A, D'Amico G, Traina M, et al. Ultrasound in the screening of patients with cirrhosis with large varices. Br Med J (Clin Res Ed) 1983;287:533.
62. Zoli M, Iervese T, Merkel C, Bianchi G, Magalotti D, Marchesini G, et al. Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. J Hepatol 1993;17:56-61.
63. Schmassmann A, Zuber M, Livers M, Jager K, Jenzer HR, Fehr HF. Recurrent bleeding after variceal hemorrhage: predictive value of portal venous duplex sonography. Am J Roentgenol 1993;160:41-7
64. Cottone M, D'Amico G, Maringhini A, Amuso M, Sciarrino E, Traina M, et al. Predictive value of ultrasonography in the screening of non-ascitic cirrhotic patients with large varices. J Ultrasound Med 1986;5:189-92.
65. Glazer GM, Laing FC, Brown TV, Gooding GAW. Sonographic demonstration of portal hypertension: the patent umbilical vein. Radiology 1980;136:161-3.
66. Schabel SI, Rittenberg GM, Javid LH, Cunningham J, Ross P. The "bull's-eye" falciform ligament: a sonographic finding of portal hypertension. Radiology 1980;135:157-9.
67. Sacerdoti D, Bolognesi M, Bombonato G, Gatta A. Paraumbilical vein patency in cirrhosis: effects on hepatic hemodynamics evaluated by Doppler sonography. Hepatology 1995;22:1689-94.
68. Michielsen PP, Duysburgh IK, Pelckmans PA. Ultrasound and duplex-Doppler in the diagnosis and follow-up of portal hypertension. Acta Gastroenterol Belg 1995;58:409-21.
69. Williams R, Condon RE, Williams HS, Blendis LM, Kreel L. Splenic blood flow in cirrhosis and portal hypertension. Clin Sci 1968;34:441-52.
70. Vilgrain V, Lebrec D, Menu Y, ScherrerA, Nahum H. Comparison between ultrasonographic signs and the degree of portal hypertension in patients with cirrhosis. Gastrointest Radiol 1990; 15:218-22.
71. Subramanyam BR, Balthazar EJ, Madamba MR, Raghavendra BN, Horii SC, Lefleur RS. Sonography of porto-systemic venous collaterals in portal hypertension. Radiology 1983;146:161-6.
72. Bolondi L, Mazziotti A, Arienti V, Casanova P, Gasbarrini G, Cavallari A, et al. Ultrasonographic study of portal venous system in portal hypertension and other portosystemic shunt operations. Surgery 1984;95:261-9.
73. Burns P, Taylor KJW, Blei AT. Doppler flowmetry and portal hypertension. Gastroenterology 1987;92:824-6
74. Miller VE, Berland LL. Pulsed Doppler duplex sonography and CT of portal vein thrombosis. Am J Roentgenol 1984;145:73-6.
75. Alpem MB, Rubin JM, Williams DM, Cape KP. Porta hepatis: dupplex Doppler ultrasound with angiographie correlation. Radiology 1987:162:53-6.
76. Scoutt LM, Zawin ML, Taylor KJW. Doppler ultrasound. Part II. Clinical applications. Radiology 1990;174:309-19.
77. Kawasaki T, Morayasu F, Nishida O, Ban N, Nakamura T, TamadaT, et al. Analysis of hepatofugal flow in portal venous system using ultrasonic Doppler duplex system. Am J Gastroenterol 1989;84:937-41.
78. Gaiani S, Bolondi L, Li Bassi S, Zironi G, Siringo S, Barbara L. Prevalence of spontaneous hepatofugal portal flow in liver cirrhosis. Clinical and endoscopie correlation in 228 patients. Gastroenterology 1991;100:160-7.
79. Zironi G, Gaiani S, Fenyves D. Value of measurement of mean portal flow velocity by Doppler flowmetry in the diagnosis of portal hypertension. J Hepatol 1992:16:298-303.
80. Siringo S, Bolondi L, Gaiani S, Sofia S, Zironi G, Rigamonti A, et al. Timing of first variceal hemorrhage in cirrhotic patients: prospective evaluation of Doppler flowmetry, endoscopy and clinical parameters. Hepatology 1994;20:66-73.
81. Cioni G, Tincani E, Cristani A, Ventura P, D'Alimonte P, Sardini C, et al. Does the measurement of portal flow velocity have any value in the identification of patients with cirrhosis at risk of digestive bleeding? Liver 1996; 16:84-7.
82. Zoli M, Cordiani MR, Brunori A. Valutazione del rischio di emorragia nella cirrosi. II Ecografia. II Fegato 1988:34:45-58.
83. Bemardi M, Trevisani F, De Palma R, Ligabue A, Capani F, Baraldini M, et al. Chronobiological evaluation of sympathoadrenergic function in cirrhosis. Relationship with arterial pressure and heart rate. Gastroenterology 1987;93:1178-86.
84. Alvarez D, Golombek D, Lopez P, de las Heras M, Viola L, Sanchez S, et al. Diurnal fluctuation of portal and systemic hemodynamic parameters in patients with cirrhosis. Hepatology 1994:20:1198-203.
85. Garcia-Pagan JC, Feu F, Castells A, Luca A, Hermida RC, Rivera F, et al. Circadian variation of portal pressure and variceal hemorrhage in patients with cirrhosis. Hepatology 1994;19:595-601.
86. Gaiani S, Bolondi L, Li Bassi S, Santi V, Zironi G, Barbara L. Effect of meal on portai hemodynamics in healty humans and patients with liver disease. Hepatology 1989;9:815-9.
87. Moriyasu F, Ban N, Nishida O, Nakamura T, MiyakeT, Uchino H, et al. Clinical application of an ultrasonic duplex system in the quantitative measurement of portal blood flow. J Clin Ultrasound 1986:14:579-88.
88. Sato S, Ohnishi K, Sugita S, Okuda K. Splenic artery and superior mesenteric artery blood flow: nonsurgical Doppler US measurements in healthy subjects and patients with chronic liver disease. Radiology 1987; 164:347-52.
89. Bolognesi M, Sacerdoti D, Merkel C, Gerunda G, Maffei-Faccioli A, Angeli P, et al. Splenic Doppler impedence indices: influence of different portal hemodynamic conditions. Hepatology 1996:23:1035-40.
90. Bolognesi M, Sacerdoti D, Bombonato GC, Angeli P, Gerunda G, Merenda R, et al. Splenic impedance indices: a useful method to monitor patients after liver transplantation? Hepatology 1998:27:674-8.
91. Sabbà C, Weltin GG, Cicchetti DV, Ferraioli G, Taylor KJW, Nakamura T, et al. Observer variability in echo-Doppler measurements of portal flow in cirrhotic patients and normal volunteers. Gastroenterology 1990;98:1603-11.
92. Sabbà C, Merkel C, Zoli M, Ferraioli G, Gaiani S, Sacerdoti D, et al. Inter-observer and inter-equipment variability of echoDoppler examination of the portal vein: effect of a cooperative training program. Hepatology 1995;21:428-33.
93. Sacerdoti D, Gaiani S, Buonamico P, Merkel C, Zoli M, Bolondi L, et al. Interobserver and interequipment variability of hepatic, splenic, and renal arterial Doppler resistance indices in normal subjects and patients with cirrhosis. J Hepatol 1997;27:986-92.
94. Tamada T, Moriyasu F, Ono S, Shimizu K, Kajimura K, Soh Y, et al. Portal blood flow: measurement with MR imaging. Radiology 1989;173:639-44.
95. Applegate GR, Thaete FL, Meyers SP, Davis PL, Talagala SL, Recht M, et al. Blood flow in the portal vein: velocity quantitation with phase-contrast MR angiography. Radiology 1993:187:253-6.
96. Shiomi S, Kuroki T, Ueda T, Takeda T, Nishiguchi S, Nakajima S, et al. Measurement of portal systemic shunting by oral and per-rectal administration of [123I]iodoamphetamine and clinical use of results. Am J Gastroenterol 1994;89:86-91.
97. D'Arienzo A, Celentano L, Cimino L, Panarese A, Lancia C, Vergara E, et al. Per-rectal portal scintigraphy with technetium99m pertechnetate for the early diagnosis of cirrhosis in patients with chronic hepatitis. J Hepatol 1992:14:188-93.
98. Urbain D, Muls V, Makhoul E, Ham HR. Prognostic value of thallium-201 per rectum scintigraphy in alcoholic cirrhosis. J Nucl Med 1994;35:832-4.
99. Dao T, Elfadel S, Bouvard G, Bouvard N, Lecointe I, Jardin-Grimaux I, et al. Assessment of portal contribution to liver perfusion by quantitative sequential scintigraphy and Doppler ultrasound in alcoholic liver cirrhosis. Diagnostic value in the detection of portal hypertension. J Clin Gastroenterol 1993:16:160-7.
100. Viallet P, Marleau D, Huet M, Martin F, Parley A, Villeneuve JP, et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension: relationship between bleeding varices and the 4 porto-hepatic gradient. Gastroenterology 1975:69:1297-300.
101. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickmann N. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985:5:419-24.
102. I02 Vihel JP, Cassigneul J, Levade M, Pascal JP. Clinical and prog-nostic significance of porto-hepatic gradient in patients with cirrhosis. Surg Gynec Obst 1982;155:347-52.
103. Lebrec D, Nouel O, Corbie M, Benhamou JP. Propranolol. A medical treatment for portal hypertension? Lancet 1980;i:180-2.
104. Gluud C, Henriksen JH, Nielsen G, and the Copenhagen Study Group for Liver Disease. Prognostic indicators in alcoholic cirrhotic man. Hepatology 1988;8:222-7.
105. Vinel JC, Caucanas JP, Cales P, Suduca JM, Voigt GG, Pascal JP. Effect of propranolol on metabolic activity of the liver in patients with alcoholic cirrhosis. J Hepatol 1988;7:186-92.
106. vinel JP, Cassigneul J, Levade M, Voigt JJ, Pascal JP. Assessment of short term prognosis with alcoholic cirrhosis by early measurement of porto-hepatic gradient. Hepatology 1986;6:116-7.
107. Groszmann RJ, Bosch J, Grace ND, Conn ND, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of the first variceal hemorrhage. Gastroenterology 1990;99:1401-7.
108. Merkel C, Bolognesi M, Bellon S, Zuin R, Noventa F, Finucci GF, et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology 1992:102:973-9.
109. Merkel C, Morabito A, Sacerdoti D, Bolognesi M, Angeli P, Gatta A. Updating prognosis of cirrhosis by Cox's regression model using Child-Pugh score and amunipyrine breath test as timedependent covariates. Ital J Gastroenterol Hepatol 1998;30:276-82.
110. Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavalencio R, Bordato J, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996;111:701-9.
111. Sacerdoti D, Merkel C, Gatta A. Importance of 1-month effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. J Hepatol 1991; 12:124-5.
112. Lin HC, Tsai YT, Lee FY, Lee SD, Hsia HC, Lin \VJ, et al. Hemodynamic evaluation of octreotide in patients with hepatitis Brelated cirrhosis. Gastroenterology 1992;103:229-34.
113. Avgerinos A, Armonis A, Raptis S. Somatostatin and octreotide in the management of acute variceal hemorrhage. Hepato-Gastroenterol 1995;42:145-50.
114. Mottet C, Sieber CC, Nauer A, Drewe J, Fried R, Larsen F, Beglinger C. Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study. Hepatology 1998;27:920-5.
115. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytical review. Hepatology 1995;22:332-53.
116. Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigau J, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984;4:1200-5.
117. Cales P, Braillon A, Jiron MJ, Lebrec D. Superior porto-systemic collateral circulation estimated by azygos blood flow in patients with cirrhosis. Lack of correlation with esophageal varices and gastrointestinal bleeding. J Hepatol 1985;l:37-46.
118. Feu F, Bordas JM, Luca A, Garcia-Pagan JC, Bosch J, Rodes J. Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. Hepatology 1991;13:917-22.
119. Gatta A, Bolognesi M, Merkel C, Finucci GF, Sacerdoti D, Ruol A. Long-term effects of β-adrenergic blockade with nadolol on hepatic and renal haemodynamics and function in cirrhotics. ClinPhysiol 1987;7:377-87.
120. Escorsell A, Ferayomi L, Bosch J, Garcia-Pagan JC, GarciaTsao G, Grace ND, et al. The portal pressure response to β-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997; 112:2012-6.
121. Bendsen F, Henriksen JH, Sorensen TIA. Propranolol and he-modynamic response in cirrhotics. J Hepatol 1991;13:144-9.
122. Sabbà C, Ferraioli G, Buonamico P, Mahal T, Taylor KJW, Lerner E, et al. A randomized study of propranolol on postprandial hyperemia in cirrhotic patients. Gastroenterology 1992;102:1009-16.
123. Merkel C, Sacerdoti D, Bolognesi M, Bombonato GC, Gatta A. Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. J Hepatol 1998;28:622-30.
124. Escorsell A, Bordas JM, Feu F, Garcia-Pagan JC, Gines A, Bosch J, et al. Endoscopie assessment of variceal volume and wall tension in cirrhotic patients: effects of pharmacological therapy. Gastroenterology 1997; 113:1640-6.
125. Groupe Français de la Prevention Pre-Primaire. Propranolol does not decrease the development of large esophageal varices in patients with cirrhosis. A controlled study. Hepatology 1995;22:252A.
126. Conn HO, Lebrec D, Terblanche J. The treatment of esophageal varices: a debate and a discussion. J Intern Med 1997;241:103-8.
127. Gelman S, Ernst EA. Hepatic circulation during sodium nitroprusside infusion in the carbon tetrachloride treated dog. Ala J Med Sci 1982;19:371-4.
128. Vinel JP, Monnin J, Combis JM, Roux D, Desmorat H, Pradere B, et al. Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis. Hepatology 1990; 11:239-42.
129. Desmorat H, Vinel JP, Lahlou O, Pipy B, Badia P, Cales P, et al. Systemic and splanchnic hemodynamic effects of molsidomine in rats with carbon tetrachloride-induced cirrhosis. Hepatology 1991;13:1181-4.
130. Hadengue A, Moureau R, Cerini R, Koshy A, Lee SS, Lebrec D. Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect. Hepatology 1989;9:83-7.
131. Vorobioff J, Garcia-Tsao G, Groszmann RJ, Aceves G, Picabea E, Villavincencio R, et al. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients. Hepatology 1989;9:88-91.
132. Lee FY, Tsai YT, Lin HC, Lee SD, Hsia HC, Lin WJ, et al. Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis B-related cirrhosis. J Hepatol 1992;15:54-8.
133. Leysen JE, Gommeren W, van Compel P, Wynants J, Jansen PF, Laduron PM. Receptor- binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. MolPharmacol 1985;27:600-11.
134. Huet PM, Giroux L, Rocheleau B. Propranolol and ritanserin: a promising combined therapy for portal hypertension. Gastroenterology 1989;96:A609.
135. Blei AT. Vasodilator therapy of portal hypertension: focus on the liver. Hepatology, 1989;9:896-9.
136. Merkel C, Gatta A, Bolognesi M, Padrini R, Finucci GF, Angeli P, et al. The calcium-channel blocker, verapamil, does not improve portal pressure in patients with alcoholic cirrhosis. Br J Clin Pharmacol 1988;26:273-7.
137. Moreau R, Lee SS, Hadengue A, Braillon A, Lebrec D. Hemodynamic effect of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. Hepatology 1987;7:148-54.
138. Roulot D, Gaudin C, Braillon A, Sekiyama T, Bacq Y, Lebrec D. Hemodynamic effects of a combination of clonidine and propranolol in conscious cirrhotic rats. Can J Physiol Pharmacol 1989;67:1369-72.
139. Van Zwieten PA, Timmermans PBM. Pharmacology and characterization of central ce-adrenoreceptors involved in the effect of centrally acting antihypertensive drugs. Chest 1983;83:340-4.
140. Albillos A, Banares R, Barrios C, Clemente G, Rossi I, Escartin P, et al. Oral administration of clonidine in patients with alcoholic cirrhosis. Gastroenterology 1992; 102:248-54.
141. Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 1991:14:231-6.
142. Henriksen JH, Moller S. Haemodynamics and fluid retention in liver disease. Ital J Gastroenterol Hepatol 1998;30:320-32.
143. Cereda JM, Roulot D, Braillon A, Moreau R, Koshy A, Lebrec D. Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. J Hepatol 1989;9:246-51.
144. Atkinson M. The effect of diuretics on portal venous pressure. Lancet 1959;ii:819-23.
145. Nevens F, Lijnen P, VanBilloen H, Fevery J. The effect of longterm treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 1996;23:1047-52.
146. Groszmann RJ, Kravetz D, Bosch J, Glickman M, Bruix J, Bredfeldt J, et al. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology 1982;2:757-62.
147. Gimson AES, Westaby D, Hergarthy J, Watson A, Williams R. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology 1986;6:410-5.
148. Tsai YT, Lay CS, Lai KH, Ng WW, Yeh YS, Wang J Y, et al. Controlled trial of vasopressin plus nitroglycerin versus vasopressin alone in the treatment of bleeding esophageal varices. Hepatology 1986;6:406-9.
149. Paquet KJ, Mercado MA, Aichner W, Cuan-Orozco F, Gad HA, Muting D. Consevative and semi-invasive modalities for treating bleeding esophageal varices. Hepato-Gastroenterol 1990;37:561-4.
150. Garcia-Pagan JC, Navasa H, Bosch J, Bru C, Pizcueta P, Rodes J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in cirrhosis. Hepatology 1990; 11:230-8.
151. Merkel C, Finucci GF, Zuin R, Bazzeria G, Bolognesi M, Sacerdoti D, et al. Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis. J Hepatol 1987;4:174-80.
152. Monnin JL, Vinel JP, Pascal JP, Dauzat M, Bruel JM, Blanc F, et al. Pulsed Doppler flowmetry assessment of molsidomine and molsidomine plus propranolol effects on portal haemodynamics in patients with cirrhosis. Hepatology 1989;10:713.
153. Hori N, Okanoue T, Sawa Y, Mori T, Kashima K. Haemodynamic effects of combined treatment with molsidomine and propranolol on portal hypertension in conscious and unrestrained cirrhotic rats. J Hepatol Gastroenterol 1986; 11:985-92.
154. Garcia-Pagan JC, Escorsell A, Feu F, Bandi JC, Moitinho E, Casado M, et al. Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis. J Hepatol 1996;24:430-5.
155. Pomier-Layrargues G, Giroux L, Rocheleau B, Huet PM. Combined treatment of portal hypertension with ritanserin and propranolol in conscious and unrestrained cirrhotic rats. Hepatology 1992;15:878-82.
156. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, et al. β-adrenergic-antagonists in the prevention of first gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med 1991;324:1532-8.
157. Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou JP, et al. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982;2:523-7.
158. Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Hermann MM, Patrick M, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986;6:101-6.
159. Luca A, Garcia-Pagan JC, Feu F, Lopez-Talavera JC, Fernandez M, Bru C, et al. Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. Hepatology 1995;21:83-8.
160. Henriksen JH, Ring-Larsen H. Renal effects of drugs used in the treatment of portal hypertension. Hepatology 1993;18:688-95.
161. Salmeron JM, Ruir Del Arbol L, Gines A, Garcia-Tsao JC, Gines P, Feu F. Renal effects of acute isosorbide-5-mononitrate in cirrhosis. Hepatology 1993;17:800-6.
162. Vorobioff J, Picabea E, Gamen G, Villavalencio R, Bordato J, Bessone F, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal hypertensive patients: long-term hemodynamic and renal effects. Hepatology 1993;18:477-84.
163. Morillas RM, Planas R, Cabré E, Galan A, Quer JC, Feu F, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long term hemodynamic and renal effects. Hepatology 1994;20:1502-8.
164. Merkel C, Gatta A, Donada C, Enzo E, Marini R, Amodio P, et al. Long-term effect of nadolol or nadolol plus isosorbide-5mononitrate on renal funtion and ascites formation in patients with cirrhosis. Hepatology 1995;22:808-13.
165. Ikegami M, Toyonaga A, Tanikawa K. Reduction of portal pressure by chronic administration of isosorbide dinitrate in patients with cirrhosis: effects on systemic and splanchnic hemodynamics and liver function. Am J Gastroenterol 1992;87:1160-4.
166. Angelico M, Carli L, Piat C, Gentile S, Rinaldi V, Bologna E, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology 1993;104:1460-5.
167. Merkel C, Marin R, Enzo E, Donada C, Cavallarin G, Torboli P, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996;348:1677-81.
168. Sarin SK, Guptan RK, Jain AK, Sundaram KR. A randomized controlled trial of endoscopie variceal band ligation for primary prophylaxis of variceal bleeding. Eur J Gastroenterol Hepatol 1996;8:337-42.
169. Lay CS, Tsai AY, Teg CY, Shyu WS, Guo WS, Wu KL, et al. Endoscopie variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology 1997;25:1346-50.
170. Moreto M, Zaballa M, Bernai A, Ibanez S, Ojembarrena E, Rodriguez A. A randomized trial of tamponade or sclerotherapy as immediate treatment for bleeding esophaegal varices. Surg Gynecol Obstet 1988:167:331-6.
171. Laine L. Ligation: endoscopie treatment of choice for patients with bleeding esophageal varices? Hepatology 1995;22:663-5.
172. Laine L, Cook D. Endoscopie ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. Ann Intern Med 1995:123:280-7.
173. Saeed ZA, Stiegmann GV, Ramirez FC, Reveille RM, Goff JS, Hepps KS, et al. Endoscopie variceal ligation is superior to combined ligation and sclerotherapy for esophageal varices: a multicenter prospective randomized trial. Hepatology 1997;25:71-4.
174. Sarin SK, Govil A, Jain AK, Guptan RC, Issar SK, Jain M, et al. Prospective randomized trial of endoscopie sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997;26:826-32.
175. Sung JJ, Chung SC, Yung MY, Lai CW, Lau JY, Lee YT, et al. Prospective randomised study of the effect of octreotide on rebleeding from esophageal varices after endoscopie ligation. Lancet 1995;346:1666-9.
176. Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995;333:555-60.
177. Cabrera J, Maynar M, Granados R, Gorriz E, Reyes R, PulidoDuque JM, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996:110:832-9.
178. Rossle M, Haag K, Ochs A, Sellinger M, Noldge G, Perarnau JM, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994:330:165-71.
179. Shiffman ML, Jeffers L, Hoofnagle JH, Tralka TS. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. Hepatology 1995:22:1591-7.
180. Banares R, Casado M, Rodriguez-Laiz JM, Camunez F, Matilla A, Echenagusia A, et al. Urgent transjugular intrahepatic portosystemic shunt for control of acute variceal bleeding. Am J Gastroenterol 1998:93:75-9.
181. Feu F, Ruiz Del Arbol L, Banares R, Planas R, Bosch J. Doubleblind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Gastroenterology 1996;111:1291-8.
182. McKee R. A study of octreotide in oesophageal varices. Digestion 1990:45:60-5.
183. Hwang JS, Lin CH, Chang CF, Lee FY, Lu WC, Hsia HC, et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepatol 1992:16:320-5.
184. Silvain C, Carpentier S, Sautereau D, Czerniochow B, Metreau JM, Fort R, et al. Terlipressin plus transdermal nitroglycerin vs octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology 1993;18:61-5.
185. Jenkins SA, Shields R, Davies M, Elias E, Turnbull AJ, Bassendine MF, et al. A multicenter randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997;41:526-33.
186. Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997;350:1495-9.
187. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. β-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997:25:63-70.
188. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995:346:1056-9.
189. Bolognesi M, Sacerdoti D, Merkel C, Bombonato G, Enzo E, Gatta A. Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: Comparison between acute and chronic effects. J Hepatol 1997:26:305-11.
190. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol 1997:26:312-24.
191. Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Tor-ras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996:334:1624-9.
192. Avgerinos A, Armonis A, Manolakopulos S, Poulianos G, Rekoumis G, Sgourou A, et al. Endoscopie sclerotherapy versus ligation in the long-term management of patients with cirrhosis after variceal bleeding. A prospectve randomized study. J Hepatol 1997:26:1034-41.
193. Cello JP. Endoscopie management of esophageal variceal hemorrhage: injection, banding, glue, octreotide, or a combination? Semin Gastrointest Dis 1997;8:179-87.
194. Grace ND. TIPS: The long and short of it. Gastroenterology 1997;112:1040-3.
195. Sarfeh IJ, Rypins EB. Partial versus total portacaval shunt in alcoholic cirrhosis. Results of a prospective, randomized clinical trial. Ann Surg 1994,219:353-61.
196. Zervos EE, Goode SE, Rosemurgy AS. Immediate and longterm portal hemodynamic consequences of small-diameter H-graft portacaval shunt. J Surg Res 1998:74:71-5.
197. Laberge JM, Ring EJ, Gordon RL, Lake JR, Doherty MM, Somberg KA, et al. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprothesis: results in 100 patients. Radiology 1993:187:413-20.
198. Merli M, Salerno F, Riggio O, De Franchis R, Fiaccadori F, Meddi P, et al. Transjugular intrahepatic portosystemic shunt versus endoscopie sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Hepatology 1998:27:40-5.
199. Selim N, Fendley MJ, Boyer TD, Galloway JR, Branum GD. Conversion of failed transjugular intrahepatic portosystemic shunt to distal splenorenal shunt in patients with Child A or B cirrhosis. Ann Surg 1998;227:600-3.